{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:35:50Z","timestamp":1793856950965,"version":"4.6.1"},"reference-count":272,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaut.2025.103500","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:19:58Z","timestamp":1763684398000},"page":"103500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The pivotal role of Interleukin-23 in the skin-gut-joint axis"],"prefix":"10.1016","volume":"157","author":[{"given":"Alen","family":"Zabotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-0909","authenticated-orcid":false,"given":"Lucia","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Maria","family":"Luchetti Gentiloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Biljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103500_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2018.00316","article-title":"Inflammation\u2013Nature\u2019s way to efficiently respond to all types of challenges: implications for understanding and managing \u201cthe Epidemic\u201d of chronic diseases","volume":"5","author":"Bennett","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/berh.2002.0263","article-title":"Seronegative spondyloarthritides","volume":"16","author":"Olivieri","year":"2002","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0720-048X(98)00035-7","article-title":"Clinical manifestations of seronegative spondylarthropathies","volume":"27","author":"Olivieri","year":"1998","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jaut.2025.103500_bib4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.autrev.2018.04.002","article-title":"Nature versus nurture in the spectrum of rheumatic diseases: classification of spondyloarthritis as autoimmune or autoinflammatory","volume":"17","author":"Generali","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103500_bib5","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jaut.2025.103500_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jaut.2025.103500_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103500_bib10","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/rheumatology\/keab461","article-title":"Interleukin-23 in perspective","volume":"60","author":"Sherlock","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103500_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2025.103500_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210172","article-title":"The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease","volume":"24","author":"Korta","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"DISCOVER-1 study group, Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"DISCOVER-2 study group, Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib19","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2025.103500_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00011-019-01235-x","article-title":"The IL-23p19\/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man","volume":"68","author":"Bridgewood","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jaut.2025.103500_bib23","doi-asserted-by":"crossref","first-page":"iv16","DOI":"10.1093\/rheumatology\/keab385","article-title":"Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints","volume":"60","author":"\u0141ukasik","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib24","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/cells9092044","article-title":"Decoding IL-23 signaling Cascade for new therapeutic opportunities","volume":"9","author":"Pastor-Fern\u00e1ndez","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2025.103500_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in Spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103500_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13048","article-title":"Tiam1\/Rac1 complex controls Il17a transcription and autoimmunity","volume":"7","author":"Kurdi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103500_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41467-019-08605-3","article-title":"Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation","volume":"10","author":"Cho","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103500_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib29","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib31","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.3390\/cells9102184","article-title":"IL-12 and IL-23\u2014Close relatives with structural homologies but distinct immunological functions","volume":"9","author":"Floss","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jaut.2025.103500_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250348","article-title":"Interleukin 23 receptor: expression and regulation in immune cells","volume":"54","author":"Mezghiche","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103500_bib34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.micinf.2019.06.009","article-title":"The IL-23\/IL-17 pathway in human chronic inflammatory diseases \u2013 new insight from genetics and targeted therapies","volume":"21","author":"Bianchi","year":"2019","journal-title":"Microb. Infect."},{"key":"10.1016\/j.jaut.2025.103500_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1488357","article-title":"JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology","volume":"16","author":"Ciccia","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2025.103500_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the Interleukin-12 family: room for discovery","volume":"50","author":"Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib38","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib40","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"IL-23-Independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib42","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/keae220","article-title":"Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort","volume":"64","author":"Ruscitti","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jaut.2025.103500_bib44","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib45","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103500_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib48","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103500_bib49","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1084\/jem.20150376","article-title":"IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization","volume":"213","author":"Yoon","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejr.2020.02.007","article-title":"Cutaneous immunohistochemical expression of interleukin-23 receptor (IL-23R) in psoriasis and psoriatic arthritis patients: relation to musculoskeletal ultrasound findings","volume":"42","author":"El-Leithy","year":"2020","journal-title":"The Egyptian Rheumatologist"},{"key":"10.1016\/j.jaut.2025.103500_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib53","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910841","article-title":"Skin barrier dysregulation in psoriasis","volume":"22","author":"Orsmond","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib56","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib57","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-Cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108937","article-title":"Crosstalk between macrophages and innate lymphoid cells (ILCs) in diseases","volume":"110","author":"Yin","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jaut.2025.103500_bib60","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib61","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib62","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7927.1","article-title":"Recent advances in understanding psoriasis","volume":"5","author":"Eberle","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.jaut.2025.103500_bib63","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib65","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature13199","article-title":"Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation","volume":"510","author":"Riol-Blanco","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103500_bib67","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1073\/pnas.0409569102","article-title":"Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris","volume":"102","author":"Chamian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2025.103500_bib68","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.4049\/jimmunol.177.7.4917","article-title":"An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12\/IL-23 in psoriasis","volume":"177","author":"Toichi","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib69","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jaut.2025.103500_bib71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1189\/jlb.0810456","article-title":"The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity","volume":"89","author":"Liu","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2025.103500_bib72","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib73","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41423-024-01218-x","article-title":"Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells","volume":"21","author":"Ohara","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111898","article-title":"IL-23 tunes inflammatory functions of human mucosal-associated invariant T (MAIT) cells","author":"Camard","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.jaut.2025.103500_bib75","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.4049\/jimmunol.1700152","article-title":"IL-22 increases permeability of intestinal epithelial tight junctions by enhancing Claudin-2 expression","volume":"199","author":"Wang","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest Res"},{"key":"10.1016\/j.jaut.2025.103500_bib77","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of inflammatory bowel disease: innate immune System","volume":"24","author":"Saez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib78","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.immuni.2018.09.011","article-title":"An interleukin-23- interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis","volume":"49","author":"Fatkhullina","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/mi.2008.28","article-title":"IL-23 and Th17 cytokines in intestinal homeostasis","volume":"1","author":"Maloy","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib80","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41385-018-0126-0","article-title":"Two distinct colonic CD14+ subsets characterized by single-cell RNA profiling in Crohn's disease","volume":"12","author":"Chapuy","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib81","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2025.103500_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2025.103500_bib83","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/ITT.S282466","article-title":"All are equal, some are more equal: targeting IL 12 and 23 in IBD \u2013 a clinical perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib84","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10875-009-9345-1","article-title":"Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease","volume":"30","author":"Eastaff-Leung","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib85","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic Colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112128","article-title":"Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells","volume":"42","author":"Jacobse","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib87","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2015.00639","article-title":"The Treg\/Th17 axis: a dynamic balance regulated by the gut microbiome","volume":"6","author":"Omenetti","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib88","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"0","author":"Bourgonje","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2025.103500_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1055914","article-title":"The role of Th17 cells in inflammatory bowel disease and the research progress","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib90","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.mucimm.2024.05.008","article-title":"IL-23 exerts dominant pathogenic functions in Crohn's disease-ileitis","volume":"17","author":"Iliopoulou","year":"2024","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/3360310","article-title":"IL-17: balancing protective immunity and pathogenesis","volume":"2023","author":"Sun","year":"2023","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/j.jaut.2025.103500_bib92","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib93","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12328-023-01893-9","article-title":"Colitis induced by IL-17A-inhibitors","volume":"17","author":"Gr\u00fcmme","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jaut.2025.103500_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13075-021-02693-7","article-title":"A role for neutrophils in early enthesitis in spondyloarthritis","volume":"24","author":"Stavre","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib95","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2010.08.010","article-title":"Interleukin-23 drives intestinal inflammation through direct activity on T cells","volume":"33","author":"Ahern","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103500_bib96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib97","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14712598.2022.2090834","article-title":"IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?","volume":"22","author":"Atzeni","year":"2022","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib98","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2665-9913(22)00334-4","article-title":"Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders","volume":"5","author":"Macleod","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103500_bib99","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.618581","article-title":"The role of the IL-23\/IL-17 axis in disease initiation in spondyloarthritis: lessons learned from animal models","volume":"12","author":"Mandour","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: a key cytokine in inflammatory diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib102","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1093\/rheumatology\/keab073","article-title":"The role of IL-23 in joint disease","volume":"60","author":"Schett","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib103","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10067-016-3500-x","article-title":"Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints","volume":"36","author":"Fiocco","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib104","doi-asserted-by":"crossref","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2025.103500_bib106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103500_bib107","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12016-015-8522-7","article-title":"Animal models of bone loss in inflammatory arthritis: from cytokines in the bench to novel treatments for bone loss in the Bedside\u2014A comprehensive review","volume":"51","author":"Alves","year":"2016","journal-title":"Clinic Rev Allerg Immunol"},{"key":"10.1016\/j.jaut.2025.103500_bib109","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.181.8.5720","article-title":"IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice","volume":"181","author":"Quinn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib110","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast Formation, and maintenance of bone mass","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib111","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/eji.200838192","article-title":"IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells","volume":"38","author":"Chen","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","volume":"11","author":"Vecellio","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2025.103500_bib114","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13075-024-03380-z","article-title":"The mode of action of IL-23 in experimental inflammatory arthritic pain and disease","volume":"26","author":"Lee","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib116","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14712598.2020.1737855","article-title":"Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis","volume":"20","author":"Rossini","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaut.2025.103500_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib118","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief Report: group 3 innate lymphoid cells in human enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib119","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/art.10125","article-title":"The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy","volume":"46","author":"McGonagle","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103500_bib120","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002592","article-title":"Peripheral spondyloarthritis and psoriatic arthritis sine psoriase: are we dealing with semantics or clinically meaningful differences?","volume":"8","author":"Ziade","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2025.103500_bib122","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003063","article-title":"Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?","volume":"9","author":"Braun","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2025.103500_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.623874","article-title":"IL-23 inhibition in ankylosing spondylitis: where did it Go wrong?","volume":"11","author":"Baeten","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib124","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, Double-Blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib126","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of Guselkumab, an Interleukin-23p19-Specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib127","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib129","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10067-018-4140-0","article-title":"Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis","volume":"37","author":"Kavanaugh","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103500_bib131","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-018-0917-3","article-title":"Tildrakizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103500_bib132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103500_bib133","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2025.103500_bib134","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib135","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/bjd\/ljad252","article-title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","volume":"189","author":"Stein Gold","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib136","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib137","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head\u2010to\u2010head comparison of ixekizumab vs. guselkumab in patients with moderate\u2010to\u2010severe plaque psoriasis: 24\u2010week efficacy and safety results from a randomized, double\u2010blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib138","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib139","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib140","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib141","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib142","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five\u2010year efficacy and safety of tildrakizumab in patients with moderate\u2010to\u2010severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib143","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103500_bib144","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib145","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"BADBIR study group, drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British association of dermatologists biologics and immunomodulators register cohort study","volume":"39","author":"Motedayen Aval","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2025.103500_bib146","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ecco-jcc\/jjad168","article-title":"Maintenance risankizumab sustains induction response in patients with Crohn's disease in a randomized phase 3 trial","volume":"18","author":"Ferrante","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib147","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1093\/ecco-jcc\/jjad212.0050","article-title":"DOP10 Risankizumab versus Ustekinumab for the achievement of Endoscopic outcomes in patients with moderate-to-severe crohn's disease: results from the phase 3b SEQUENCE trial","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib148","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib149","doi-asserted-by":"crossref","unstructured":"R. Panaccione, S. Danese, B. Feagan, G. D'Haens, A. Afzali, W. Reinisch, J. Pan\u00e9s, Efficacy and safety of Guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the Galaxi 2 & 3 Phase 3 studies, n.d. https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-guselkumab-therapy-in-patients-with-moderately-to-severely-active-crohns-disease-results-of-the-galaxi-2-3-phase-3-studies\/(accessed June 23, 2025).","DOI":"10.1016\/S0016-5085(24)05019-4"},{"key":"10.1016\/j.jaut.2025.103500_bib150","doi-asserted-by":"crossref","first-page":"i1724","DOI":"10.1093\/ecco-jcc\/jjae190.1091","article-title":"P0917 corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn's disease: phase 3 GALAXI 2\/3 results through week 48","volume":"19","author":"Pan\u00e9s","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib151","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjad212.0035","article-title":"OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn's disease: results from the phase 3 VIVID 1 study","volume":"18","author":"Jairath","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib152","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.12414","article-title":"INSPIRE and COMMAND study group, Risankizumab for ulcerative colitis: two randomized clinical trials","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2025.103500_bib153","first-page":"i1732","article-title":"QUASAR Clinical Investigators, P954 cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study","volume":"18","author":"Rubin","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib154","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib155","doi-asserted-by":"crossref","unstructured":"C.K. Kerut, M.J. Wagner, C.P. Daniel, C. Fisher, E.J. Henderson, C.R. Burroughs, S. Amarasinghe, O. Willett, S. Ahmadzadeh, G. Varrassi, S. Shekoohi, A.D. Kaye, Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: a review of its mechanism, use, and clinical effectiveness, Cureus 15 (n.d.) e51405. https:\/\/doi.org\/10.7759\/cureus.51405.","DOI":"10.7759\/cureus.51405"},{"key":"10.1016\/j.jaut.2025.103500_bib156","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib157","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib158","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib159","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 100-Week results from the KEEPsAKE 2 randomized clinical trial","volume":"11","author":"\u00d6st\u00f6r","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2025.103500_bib160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase 3 KEEPsAKE 1 randomized clinical trial","volume":"11","author":"Kristensen","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2025.103500_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003977","article-title":"Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2025.103500_bib162","unstructured":"Sun pharmaceutical industries limited, ILUMYA_US_Prescribing_Information, n.d. https:\/\/www.ilumya.com\/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf."},{"key":"10.1016\/j.jaut.2025.103500_bib163","unstructured":"AbbVie, SKYRIZI prescribing information, n.d. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf."},{"key":"10.1016\/j.jaut.2025.103500_bib164","unstructured":"Janssen Biotech, TREMFYA Prescribing information, n.d. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf."},{"key":"10.1016\/j.jaut.2025.103500_bib165","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib167","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib168","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib169","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib170","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaut.2025.103500_bib171","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib172","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/jcm13020495","article-title":"Effectiveness, tolerability, and drug survival of Risankizumab in a real-world setting: a three-year retrospective multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"13","author":"Gargiulo","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib173","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","volume":"90","author":"Strober","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib174","article-title":"Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis","author":"Rompoti","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2025.103500_bib175","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with Guselkumab, Ixekizumab, Secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib176","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2025.103500_bib177","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae024","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","author":"Sands","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib178","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Spanish DILI registry, SLatinDILI network, Safer and faster Evidence-based translation consortium, use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2025.103500_bib179","doi-asserted-by":"crossref","first-page":"i2023","DOI":"10.1093\/ecco-jcc\/jjae190.1275","article-title":"P1101 real-world effectiveness and safety of Risankizumab in Crohn's disease","volume":"19","author":"McShane","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.dld.2023.11.012","article-title":"Anti-IL23 in inflammatory bowel disease patients with dermatological indication: the shared gastroenterological-dermatological clinic experience","volume":"56","author":"Ribaldone","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib181","doi-asserted-by":"crossref","first-page":"i1586","DOI":"10.1093\/ecco-jcc\/jjae190.1006","article-title":"The PAN UK risankizumab CD study group, P0832 real-world effectiveness of risankizumab in Crohn's disease: the UK experience","volume":"19","author":"Elford","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib182","author":"Lars"},{"key":"10.1016\/j.jaut.2025.103500_bib183","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jaut.2025.103500_bib184","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clicom.2023.07.001","article-title":"IL-23 inhibitors to treat psoriatic arthritis: a systematic review & meta-analysis of randomized controlled trials","volume":"4","author":"Vahidy","year":"2023","journal-title":"Clinical Immunology Communications"},{"key":"10.1016\/j.jaut.2025.103500_bib185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s13555-023-00893-4","article-title":"The BIOREP study group, long-term efficacy, safety, and drug survival of Guselkumab in patients with psoriasis: Real-World data from the Czech Republic BIOREP registry","volume":"13","author":"Hugo","year":"2023","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib186","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/ijd.16849","article-title":"Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas","volume":"62","author":"Vaiopoulos","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib187","doi-asserted-by":"crossref","unstructured":"Y. Tada, Y. Sugiura, M. Kamishima, S. Takahashi, Y. Tanaka, J. Masuda, K. Yamanaka, Real-world safety and effectiveness of guselkumab in patients with psoriasis: a post-marketing surveillance study through up to week 52 in Japan, The Journal of Dermatology n\/a (n.d.). https:\/\/doi.org\/10.1111\/1346-8138.17710.","DOI":"10.1111\/1346-8138.17710"},{"key":"10.1016\/j.jaut.2025.103500_bib188","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20930116","article-title":"Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaut.2025.103500_bib189","article-title":"No significant effects of IL-23 on initiating and perpetuating the axial spondyloarthritis: the reasons for the failure of IL-23 inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib191","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jaut.2025.103500_bib192","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103500_bib193","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2023-eular.3268","article-title":"POS1524 durable clinically-meaningful improvements in health-related quality of life, fatigue, pain, and work productivity among patients with active psoriatic arthritis treated with risankizumab at week 100","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib194","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib195","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib196","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","article-title":"Prevalence and incidence of psoriasis and psoriatic arthritis","volume":"78","author":"Sewerin","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib197","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","author":"Lembke","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib198","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2025.103500_bib199","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12664-023-01430-z","article-title":"Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019)","volume":"43","author":"Dharni","year":"2024","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.jaut.2025.103500_bib200","series-title":"Psoriatic Arthritis (Psa) is Common Among Patients with Psoriasis and Family Medical Clinic Attendees","author":"Brockbank","year":"2001"},{"key":"10.1016\/j.jaut.2025.103500_bib201","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","article-title":"Prevalence of joint disease in patients with psoriasis: implications for therapy","volume":"4","author":"Zachariae","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib202","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1365-2133.2007.08139.x","article-title":"Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience","volume":"157","author":"Mody","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib203","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib204","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and Bidirectional Association between psoriasis and inflammatory bowel Disease-A systematic review and meta-analysis","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jaut.2025.103500_bib205","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241227037","article-title":"The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis","volume":"17","author":"Shani","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jaut.2025.103500_bib206","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000514030","article-title":"Incidence of psoriasis in patients with inflammatory bowel disease: a nationwide population-based matched cohort Study","volume":"237","author":"Moon","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.jaut.2025.103500_bib207","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","article-title":"Incidence and risk of inflammatory bowel disease in patients with Psoriasis\u2014A nationwide 20-Year cohort study","volume":"139","author":"Egeberg","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib208","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s10067-016-3374-y","article-title":"Gastrointestinal comorbidities in patients with psoriatic arthritis","volume":"35","author":"Zohar","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib209","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","article-title":"The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis","volume":"61","author":"Makredes","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib210","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1136\/annrheumdis-2024-eular.1656","article-title":"Ab1335 what is the real association's frequency of immune-mediated inflammatory diseases? Study of 6686 cases","volume":"83","author":"Robin","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib211","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/acr.20401","article-title":"Incidence of arthritis in a prospective cohort of psoriasis patients","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2025.103500_bib212","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/acr.20496","article-title":"Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2025.103500_bib213","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib214","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11926-015-0540-1","article-title":"Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence","volume":"17","author":"Ogdie","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib215","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2025.103500_bib216","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib217","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1080\/09546634.2021.1942423","article-title":"A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis","volume":"33","author":"Gottlieb","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaut.2025.103500_bib218","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib219","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000001228","article-title":"Autoantibodies in psoriatic arthritis: are they of pathogenic relevance?","volume":"133","author":"Zhu","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaut.2025.103500_bib220","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3906\/sag-2011-235","article-title":"Autoimmunity in psoriatic arthritis: pathophysiological and clinical aspects","volume":"51","author":"Emmungi\u0307l","year":"2021","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1346757","article-title":"From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature","volume":"11","author":"Lob\u00e3o","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24924-w","article-title":"Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + ROR\u03b3t + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies","volume":"12","author":"Pouw","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib223","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic arthritis: pathogenesis and targeted therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103500_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.01.006","article-title":"Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics","author":"Gisondi","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib225","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s13555-021-00565-1","article-title":"Musculoskeletal imaging for dermatologists: techniques in the diagnosis and management of psoriatic arthritis","volume":"11","author":"Gottlieb","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib226","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00487","article-title":"Ultrasound imaging in psoriatic arthritis: what have we learnt in the last five years?","volume":"7","author":"Dubash","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.jaut.2025.103500_bib227","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinthera.2023.07.017","article-title":"Utility of musculoskeletal ultrasound in psoriatic arthritis","volume":"45","author":"Hum","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib228","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kex179","article-title":"On behalf of the Musculoskeletal ultrasound study group of the Italian society of Rheumatology, Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review","volume":"56","author":"Zabotti","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103500_bib229","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/jpm14060550","article-title":"Ultrasonographic insights into peripheral psoriatic arthritis: updates in diagnosis and monitoring","volume":"14","author":"Bonfiglioli","year":"2024","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.jaut.2025.103500_bib230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib231","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003143","article-title":"Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce","volume":"9","author":"De Marco","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2025.103500_bib232","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib233","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib234","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103500_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.06.106","article-title":"Risk of developing inflammatory arthritis in psoriasis patients initiating treatment with biologics: a population based analysis","author":"Strober","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib236","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/annrheumdis-2024-eular.5872","article-title":"Evaluation of the risk of psoriatic arthritis in patients with psoriasis undergoing biological treatment. Global population study (trinetx)","volume":"83","author":"Joven-Ib\u00e1\u00f1ez","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib237","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-023-01072-1","article-title":"Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors","volume":"14","author":"Errichetti","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib239","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-021-00650-5","article-title":"Arthritis interception in patients with psoriasis treated with Guselkumab","volume":"12","author":"Zabotti","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib240","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaut.2025.103500_bib241","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/BOR.0000000000000569","article-title":"The ties that bind: skin, gut and spondyloarthritis","volume":"31","author":"Gracey","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib242","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib243","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/BOR.0b013e3283393807","article-title":"Interactions between gut inflammation and arthritis\/spondylitis","volume":"22","author":"Jacques","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib244","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2018.01.014","article-title":"The role of gut microbiota and IL-23\/IL-17 pathway in ankylosing spondylitis immunopathogenesis: new insights and updates","volume":"196","author":"Babaie","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jaut.2025.103500_bib245","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s10067-022-06315-8","article-title":"Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib246","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11926-024-01136-x","article-title":"Sequence of events in the pathogenesis of axial spondyloarthritis: a current Review\u20142023 SPARTAN meeting proceedings","volume":"26","author":"Srinath","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib247","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/art.42627","article-title":"Gut inflammation in axial spondyloarthritis patients is characterized by a marked type 17 skewed mucosal innate-like T cell signature","volume":"75","author":"Mortier","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib248","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.932393","article-title":"Cytokine competent gut-joint migratory T cells contribute to inflammation in the joint","volume":"13","author":"Lefferts","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib249","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-019-0834-9","article-title":"ILC3 in axial spondyloarthritis: the gut angle","volume":"21","author":"Mauro","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2025.103500_bib250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaut.2025.103500_bib251","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/microorganisms11071849","article-title":"The role of gut dysbiosis in the loss of intestinal immune cell functions and viral pathogenesis","volume":"11","author":"Fakharian","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.jaut.2025.103500_bib252","doi-asserted-by":"crossref","first-page":"454","DOI":"10.22203\/eCM.v041a29","article-title":"Gut microbial-derived short-chain fatty acids and bone: a potential role in fracture healing","volume":"41","author":"Wallimann","year":"2021","journal-title":"Eur. Cell. Mater."},{"key":"10.1016\/j.jaut.2025.103500_bib253","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800100-4.00003-9","article-title":"The role of short-chain fatty acids in health and disease","volume":"121","author":"Tan","year":"2014","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jaut.2025.103500_bib254","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103500_bib255","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103500_bib256","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2025.103500_bib257","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02386-14","article-title":"Inflammasome activation contributes to Interleukin-23 production in response to Clostridium difficile","volume":"6","author":"Cowardin","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.jaut.2025.103500_bib258","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/art.41644","article-title":"Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis","volume":"73","author":"Guggino","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib259","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm0911-1055","article-title":"Autoimmunity's collateral damage: gut microbiota strikes \u201cback,\u201d","volume":"17","author":"Cua","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103500_bib260","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/nu15041057","article-title":"No evidence of a genetic causal relationship between ankylosing spondylitis and Gut microbiota: a two-sample Mendelian randomization Study","volume":"15","author":"Yang","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jaut.2025.103500_bib261","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-Sample mendelian randomization Study","volume":"158","author":"Freuer","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib262","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2025.103500_bib263","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jaut.2025.103500_bib264","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/BOR.0000000000000232","article-title":"Bone remodeling in psoriasis and psoriatic arthritis: an update","volume":"28","author":"Paine","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib265","first-page":"1241","article-title":"Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms","volume":"27","author":"Scarpa","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103500_bib266","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s13555-024-01121-3","article-title":"The role of the gut-joint axis in the care of psoriatic arthritis: a two-sample bidirectional mendelian randomization study","volume":"14","author":"Gan","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jaut.2025.103500_bib267","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"DISCOVER-2 study group, Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103500_bib268","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","article-title":"Risankizumab: a review in moderate to severe plaque psoriasis","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103500_bib269","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2025.103500_bib270","doi-asserted-by":"crossref","unstructured":"F. Lusetti, F. D'Amico, M. Allocca, F. Furfaro, A. Zilli, G. Fiorino, T.L. Parigi, S. Radice, L. Peyrin-Biroulet, S. Danese, Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease, Immunotherapy 16 (n.d.) 581\u2013595. https:\/\/doi.org\/10.2217\/imt-2023-0219.","DOI":"10.2217\/imt-2023-0219"},{"key":"10.1016\/j.jaut.2025.103500_bib271","unstructured":"European medicines agency, Ilumetri - Tildrakizumab (SMPC), n.d. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri."},{"key":"10.1016\/j.jaut.2025.103500_bib272","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:07:04Z","timestamp":1773817624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":272,"alternative-id":["S0896841125001453"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103500","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pivotal role of Interleukin-23 in the skin-gut-joint axis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103500"}}